DK0458696T3 - Anvendelse af 1-(2-naphtylethyl)-4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridin til fremstilling af et lægemiddel til behandling af cerebrale og neuronale sygdomme - Google Patents

Anvendelse af 1-(2-naphtylethyl)-4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridin til fremstilling af et lægemiddel til behandling af cerebrale og neuronale sygdomme

Info

Publication number
DK0458696T3
DK0458696T3 DK91401311.5T DK91401311T DK0458696T3 DK 0458696 T3 DK0458696 T3 DK 0458696T3 DK 91401311 T DK91401311 T DK 91401311T DK 0458696 T3 DK0458696 T3 DK 0458696T3
Authority
DK
Denmark
Prior art keywords
naphthylethyl
tetrahydropyridine
trifluoromethylphenyl
cerebral
medicament
Prior art date
Application number
DK91401311.5T
Other languages
Danish (da)
English (en)
Inventor
Francois Xavier Coude
Jacqueline Fournier
Umberto Guzzi
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of DK0458696T3 publication Critical patent/DK0458696T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK91401311.5T 1990-05-22 1991-05-21 Anvendelse af 1-(2-naphtylethyl)-4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridin til fremstilling af et lægemiddel til behandling af cerebrale og neuronale sygdomme DK0458696T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9006399A FR2662355B1 (fr) 1990-05-22 1990-05-22 Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Publications (1)

Publication Number Publication Date
DK0458696T3 true DK0458696T3 (da) 1996-05-20

Family

ID=9396855

Family Applications (2)

Application Number Title Priority Date Filing Date
DK91401311.5T DK0458696T3 (da) 1990-05-22 1991-05-21 Anvendelse af 1-(2-naphtylethyl)-4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridin til fremstilling af et lægemiddel til behandling af cerebrale og neuronale sygdomme
DK94403014T DK0655247T3 (da) 1990-05-22 1991-05-21 Anvendelse af vinkristin til bestemmelse af substanser på neuralt niveau

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK94403014T DK0655247T3 (da) 1990-05-22 1991-05-21 Anvendelse af vinkristin til bestemmelse af substanser på neuralt niveau

Country Status (16)

Country Link
US (3) US5229389A (OSRAM)
EP (2) EP0655247B1 (OSRAM)
JP (2) JP2618115B2 (OSRAM)
KR (1) KR0181330B1 (OSRAM)
AT (2) ATE132369T1 (OSRAM)
BR (1) BR9105015A (OSRAM)
CA (2) CA2042974C (OSRAM)
CY (1) CY2283B1 (OSRAM)
DE (2) DE69132797T2 (OSRAM)
DK (2) DK0458696T3 (OSRAM)
FR (1) FR2662355B1 (OSRAM)
HU (1) HU208922B (OSRAM)
IE (1) IE911707A1 (OSRAM)
IL (3) IL112167A (OSRAM)
TW (1) TW216771B (OSRAM)
ZA (1) ZA913865B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0192386A (ja) * 1987-10-05 1989-04-11 Hitachi Ltd 密閉循環型吸収式冷凍機及び吸収式冷凍機用吸収液
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
US5557209A (en) * 1990-12-20 1996-09-17 Hewlett-Packard Company Identification of pin-open faults by capacitive coupling through the integrated circuit package
FR2672213B1 (fr) 1991-02-05 1995-03-10 Sanofi Sa Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
FR2690158B1 (fr) * 1992-04-17 1994-07-22 Sanofi Elf Nouveau derive arylpiperidinique, procede pour sa preparation et compositions pharmaceutiques le contenant.
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.
US5698565A (en) * 1995-06-09 1997-12-16 Hoffmann-La Roche Inc. Use of phenoxy-pyridine derivatives
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2740343B1 (fr) * 1995-10-26 1999-01-22 Sanofi Sa Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
US6043251A (en) * 1995-10-26 2000-03-28 Sanofi Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyr idine for preparing drugs for treating amyotrophic lateral sclerosis
EP0890105B1 (en) * 1996-03-29 2006-11-22 The Trustees Of Boston University Methods related to Alzheimer's disease for diagnosis, manufacture of medicaments and screening of substances and beta-amyloid related peptides
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2757161B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa Diphenylalkyl-tetrahydropyridines
FR2757510B1 (fr) * 1996-12-23 2000-01-07 Sanofi Sa Forme microparticulaire d'un derive de tetrahydropyridine
FR2757512B1 (fr) * 1996-12-24 1999-03-12 Sanofi Sa Utilisation de benzoylalkyl-1-1,2,3,6-tetrahydropyridines
WO1998033502A1 (fr) * 1997-02-03 1998-08-06 Sanofi-Synthelabo Utilisation du 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
FR2763847B1 (fr) * 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
FR2771007B1 (fr) * 1997-11-14 2000-12-01 Sanofi Sa Association de principes actifs pour le traitement de la demence senile du type alzheimer
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
DE19751949A1 (de) 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
TWI237035B (en) * 1998-07-24 2005-08-01 Polyplastics Co Polyacetal copolymer
CN102727501A (zh) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Also Published As

Publication number Publication date
DE69115989T2 (de) 1996-08-22
US5229389A (en) 1993-07-20
EP0458696B1 (fr) 1996-01-03
DE69115989D1 (de) 1996-02-15
BR9105015A (pt) 1993-05-25
HUT59824A (en) 1992-07-28
US5468753A (en) 1995-11-21
CY2283B1 (en) 2003-07-04
EP0655247A1 (fr) 1995-05-31
IL98175A (en) 1996-01-19
CA2365832A1 (en) 1991-11-23
JPH09132535A (ja) 1997-05-20
JPH04226917A (ja) 1992-08-17
AU636488B2 (en) 1993-04-29
KR0181330B1 (ko) 1999-03-20
CA2365832C (en) 2007-08-07
IL112167A (en) 1996-01-31
HK1001471A1 (en) 1998-06-19
JP2954029B2 (ja) 1999-09-27
IE20011078A1 (en) 2002-03-20
HU911729D0 (en) 1991-12-30
EP0655247B1 (fr) 2001-10-31
EP0458696A2 (fr) 1991-11-27
JP2618115B2 (ja) 1997-06-11
HU208922B (en) 1994-02-28
IL98175A0 (en) 1992-06-21
EP0458696A3 (en) 1992-03-18
ATE207747T1 (de) 2001-11-15
FR2662355B1 (fr) 1994-11-10
DK0655247T3 (da) 2002-02-18
ZA913865B (en) 1992-02-26
KR910019617A (ko) 1991-12-19
IE911707A1 (en) 1991-12-04
DE69132797T2 (de) 2002-05-29
CA2042974C (en) 2002-09-17
ATE132369T1 (de) 1996-01-15
IL112167A0 (en) 1995-03-15
US5270320A (en) 1993-12-14
CA2042974A1 (en) 1991-11-22
AU7713391A (en) 1991-11-28
TW216771B (OSRAM) 1993-12-01
DE69132797D1 (de) 2001-12-06
FR2662355A1 (fr) 1991-11-29

Similar Documents

Publication Publication Date Title
DK0458696T3 (da) Anvendelse af 1-(2-naphtylethyl)-4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridin til fremstilling af et lægemiddel til behandling af cerebrale og neuronale sygdomme
ATE194593T1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
DE58904674D1 (de) 4,6-bis-trichlormethyl-s-triazin-2-ylgruppen enthaltende heterocyclische verbindungen, verfahren zu ihrer herstellung und lichtempfindliches gemisch, das diese verbindungen enthaelt.
DE3882245D1 (de) Magnetoresistiver kopf und verfahren zu seiner herstellung.
DE69100547D1 (de) Methode und Vorrichtung zum elektrochemischen Bearbeiten der Spritzöffnungen von Brennstoff-Einspritzdüsen.
DE3884641D1 (de) Aufzeichnungsflüssigkeit und Aufzeichnungsverfahren unter Verwendung derselben.
DE3886046D1 (de) Sich selbst stumpf machende nadeleinheit sowie diese aufweisende vorrichtung.
DE69000704D1 (de) Vorrichtung zum lesen der konturen, insbesondere der rahmen von brillen.
DE3777761D1 (de) 2-(2-substituierte benzoyl)-4-(substituierte oxy oder substituierte thio)-1,3-cyclohexandione, verfahren zu deren herstellung, sowie sie enthaltende herbizide zusammensetzung.
DE59200004D1 (de) Thermisch gespaltenes zirkonsilikat, verfahren zu seiner herstellung und verwendung.
DE3582211D1 (de) Strahlungsempfindliches aufzeichnungsmaterial und verfahren zu seiner herstellung.
DE69635213D1 (de) Verwendung von Olanzapin zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen
DE3764056D1 (de) Verfahren und vorrichtung zur aufzeichnung und/oder auswertung des bewegungsverhaltens von versuchstieren.
AT383491B (de) Vorrichtung zum verabreichen von voll- oder sitz- baedern, insbesondere unter verwendung von peloid
DE68905837D1 (de) 2-(alkyl-cyclohexyl)-1-propanol, verfahren zu dessen herstellung und ihn enthaltende riechstoffzusammensetzung.
ATE174002T1 (de) Verfahren zur reinigung von abfüllanlagen
NO901303L (no) Nye benzotiopyranylaminer.
DE3889043D1 (de) N-(substituiertes Alkyliden)-1,2,3,4-tetrahydro-9-acridinamine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
DE3875543D1 (de) 1-(2-(phenylmethyl)phenyl)-piperazin-verbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen.
DE3862788D1 (de) Fluessige oxydationsmodifizierte ethylenische statistische copolymere, verfahren zur herstellung und deren verwendung.
DE3870912D1 (de) 4,4'-(perfluorisopropyliden)dicyclohexanol, dessen abkoemmling und verfahren zur herstellung davon.
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
DE59002266D1 (de) Verwendung von 4-(hydroxydi-phenylmethyl)-1-piperidyl-phenylalkan-derivaten zur herstellung eines antihistaminikums.
Mahon Early quantitative studies of neuropsychological impairment, 1899–1939.
Ortiz et al. EEG alpha symmetry during phonemic discrimination.